Jonathan Desantis, MD
Cardiovascular Disease · Albany, NYNPI 1831197268
Payments from drug & device makers
Across 525 payments — averaging $112.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$21K
- Amarin Pharma, Inc.$20K
- Esperion Therapeutics, Inc.$11K
- Novartis$2K
- Amgen$901
- Boehringer Ingelheim$767
- plus $4K from 28 others
What the payments were for
- Speaking & faculty fees$27,93072%
- Travel & lodging$1,8485%
- Food & beverage$8,60022%
- Education$1530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 11 | $20,613 |
| Amarin Pharma, Inc. | 40 | $20,185 |
| Esperion Therapeutics, Inc. | 19 | $11,232 |
| Novartis | 184 | $1,577 |
| Amgen | 52 | $901 |
| Boehringer Ingelheim | 47 | $767 |
| Johnson & Johnson | 31 | $488 |
| Arbor Pharmaceuticals, Inc. | 28 | $447 |
| Boston Scientific | 4 | $431 |
| E.r. Squibb & Sons, L.L.C. | 17 | $403 |
| AstraZeneca | 14 | $331 |
| Novo Nordisk | 20 | $302 |
| Regeneron Healthcare Solutions, Inc. | 5 | $178 |
| Sanofi-aventis U.S. LLC | 4 | $176 |
| Scpharmaceuticals Inc. | 8 | $152 |
| Medtronic | 1 | $139 |
| Pfizer | 7 | $106 |
| Azurity Pharmaceuticals, Inc. | 5 | $87 |
| Actelion Pharmaceuticals US, Inc. | 4 | $83 |
| Lilly USA, LLC | 4 | $70 |
| Lexicon Pharmaceuticals, Inc. | 3 | $58 |
| Baxter Healthcare | 1 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $37 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Bridgebio Pharma, Inc. | 1 | $21 |
| Agepha Pharma FZ LLC | 1 | $20 |
| Philips North America LLC | 1 | $20 |
| Medicomp Inc | 1 | $19 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Ionis Pharmaceuticals, Inc. | 1 | $14 |
| Janssen Scientific Affairs, LLC | 1 | $12 |
| Irhythm Technologies, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$59,030 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 441 | $602,340 |
| Repatha SureclickEvolocumab | 135 | $122,776 |
| EntrestoSacubitril/Valsartan | 73 | $101,782 |
| XareltoRivaroxaban | 91 | $85,701 |
| Praluent PenAlirocumab | 37 | $18,112 |
| EdarbiAzilsartan Medoxomil | 22 | $17,393 |
| NexlizetBempedoic Acid/Ezetimibe | 17 | $17,163 |
| WegovySemaglutide | 13 | $16,875 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 27 | $15,764 |
| BrilintaTicagrelor | 17 | $14,943 |
| NexletolBempedoic Acid | 12 | $13,437 |
| Ranolazine ErRanolazine | 65 | $9,899 |
| Irbesartan | 306 | $9,603 |
| Metoprolol Succinate | 593 | $9,015 |
| Atorvastatin Calcium | 647 | $7,003 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $106 | $602,340441 claims |
| NovartisEntresto | $1,577 | $101,78273 claims |
| Johnson & JohnsonXarelto | $488 | $85,70191 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $447 | $33,15649 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $11,232 | $30,60129 claims |
| Novo NordiskWegovy | $302 | $16,87513 claims |
| AstraZenecaBrilinta | $331 | $14,94317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Albany
- Augustin DelagoAlbany$2M
- Rizwan AlimohammadAlbany$624K
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.